Andrx
This article was originally published in The Tan Sheet
Executive Summary
Generics firm met with FDA to discuss "inspectional observations" detailed in two Form 483s issued by the agency earlier this year, Andrx announces Sept. 8. The firm detailed corrective measures implemented at its Florida manufacturing facilities, and believes FDA "will be satisfied with the company's corrective action plan, that no regulatory action will be taken" and that the firm will continue to have its ANDAs approved "in due course." CEO Thomas Rice says Andrx is "committed to quality throughout its organization"...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.